To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
Expanding Possibilities Through Entrepreneurial Science
Entrepreneurial science means pursuing bold pathways over conventional ones. And nowhere is that clearer than how we work with others through our Immunology Innovation Program (IIP).
IIP Is Invention and
Co-Creation in Action
At argenx, we’re committed to seeking out the seeds of innovation and helping them grow. Our IIP is the key. It helps us partner with leading academic and clinical researchers all over the world to advance breakthrough immunology insights.
It’s a partnership based on working closely and sharing resources. We combine their deep disease and target biology expertise with our world-class antibody engineering and development capabilities. The goal: to transform promising ideas into groundbreaking antibody therapies.
A Shared Commitment
The most successful partnerships are built on shared purpose. For those in the IIP, that goal is pushing novel immunology insights into differentiated antibody-based medicines. And it’s made possible by a mutual dedication to transparency, long-term commitment, and shared success.
The IIP reflects how argenx works best. Alongside collaborators, we strive to advance science that has the potential to redefine what’s possible for patients.
Collective Creations
- Adimanebart
- ABBV-115
- ARGX-118
- Efgartigimod
- The Power of Partnerships
Adimanebart
Adimanebart (previously ARGX-119) was developed in partnership with Maartje Huijbers, Ph.D., and Steve Burden, Ph.D., to activate muscle-specific kinase.
ARGX-115
ARGX-115 (now ABBV-151) was built in collaboration with Prof. Sophie Lucas, M.D., P.hD., as humanized monoclonal antibody inhibitor of GARP-TGF-β1.
ARGX-118
ARGX-118 was created with Prof. Bart Lambrecht, M.D., P.hD., as a highly differentiated antibody against Galectin-10.
Efgartigimod
Built in collaboration with Prof. E. Sally Ward, Ph.D., Efgartigimod designed as a human IgG1 antibody Fc-fragment, a natural ligand of the neonatal Fc receptor (FcRn).
The Power of Partnerships
To us Partnership is part of our DNA core to who we are. IIP allows us to work alongside leading academic and clinical researchers. Together we’re driven by our shared ambition of removing boundaries, simplifying complexities, and unlocking breakthrough therapies.
Let’s Innovate Together
Respect for our partners’ vision and expertise is the bedrock of the IIP. If you have a spirit for scientific entrepreneurship, we would like to hear about what you’re doing. We offer antibody engineering capabilities and a pathway to convert immunology breakthroughs into clinical development candidates.
Together we can innovate faster for people who need progress now.
A Growing Global Network
argenx is helping to drive innovation in immunology and antibody discovery by partnering with collaborators from Boston to Bern and beyond.
Select a Country
- All
- United States of America
- Switzerland
- France
- Belgium
- Germany
- Italy
- Netherlands
- United Kingdom
- Australia
University of Pennsylvania
3451 Walnut Street, Philadelphia, PA 19104
NYU Grossman School of Medicine
550 1st Avenue, New York, NY 10016
Ludwig Cancer Research
600 Third Avenue, New York, New York 10016
UT Southwestern
5323 Harry Hines Blvd, Dallas, TX 75390
Massachusetts General Hospital
55 Fruit Street, Boston, MA 02114
Johns Hopkins University
3400 N. Charles Street, Baltimore, MD 21218
Bern University
Hochschulstrasse 6, 3012 Bern, Switzerland
INSERM
101 rue de Tolbiac, Cedex 13, Paris, 75654
Institut de Duve
Avenue Hippocrate 75, 1200 Brussels, Belgium
Université Catholique de Louvain
Pl. de l'Université 1, 1348 Ottignies-Louvain-la-Neuve, Belgium
Flemish Institute for Biotechnology
VIB, Suzanne Tassierstraat 1, 9052 Ghent, Belgium
Hasselt University
Martelarenlaan 42, 3500 Hasselt, Belgium
University Düsseldorf
Rheinstraße 3, 40213 Düsseldorf, Germany
Turin University
Via Giuseppe Verdi 8, 10124 Torino TO, Italy
Leiden University
Rapenburg 70, 2311 EZ Leiden, The Netherlands
Utrecht University
Heidelberglaan 8, 3584 CS Utrecht, The Netherlands
Sanquin
Plesmanlaan 125, 1066 CX Amsterdam, Netherlands
University of Edinburgh
School of Physics and Astronomy University of Edinburgh, James Clerk Maxwell Building, Peter Guthrie Tait Road, Edinburgh, EH9 3FD
University of South Australia
101 Currie Street, Adelaide, SA 5000, Australia
Monash University
Wellington Road, Clayton, Victoria 3800, Australia
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Case Studies
Discover the science and stories of how we’re helping expand possibilities in immunology.
Co-Creation in Action
See what happens when our team takes promising leaps alongside leading scientists, physicians, and researchers.
Publications
Peer-reviewed publications that reflect our range of immunology innovation.
